Pay-For-Performance Deals Help Solve ATMP Access Barriers In Europe
New regulations on health technology assessments pose both a threat and an opportunity for getting advanced therapies to market in Europe, while pay-for-performance deals can solve the problem of high up-front payments, said speakers at an event organized by the Alliance for Regenerative Medicine.
You may also be interested in...
Legal and industry expert Alexander Natz sets out key questions and answers to help companies prepare for new EU regulations on health technology assessments, one of the biggest developments to affect the pharmaceutical industry in over a decade.
While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.
Europe is becoming less competitive in the advanced therapy space, something that is reflected in the number of EU ATMP marketing authorization withdrawals, speakers said at an event organized by the Alliance for Regenerative Medicine.